DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE – Yahoo Finance

LA JOLLA, Calif., January 10, 2023–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the Defense Health Agency’s Lab Joint Working Group has recommended the Company’s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by TRICARE. TRICARE is the health care program for uniformed service members, retirees and their families around the world.
This coverage recommendation makes the foundational assay of the DMT available to TRICARE’s approximately 9 million members and beneficiaries of the Military Health System. The DMT is the first non-invasive approach to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV).
"We’re proud to support TRICARE in bringing our non-invasive melanoma test to our nation’s military heroes and their families," said Dan Visage, senior vice president of payor access, DermTech. "The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. We look forward to working with the TRICARE team to take the additional steps needed to allow for full availability of our test to its members in the next few months."
DermTech’s total covered lives in the U.S. are now approximately 113 million, which includes 68 million for Medicare/Medicare Advantage and 45 million for commercial and governmental payers.
About The DermTech Melanoma Test
DermTech originally marketed its foundational assay under the name Pigmented Lesion Assay (PLA). The PLA assessed pigmented skin lesions, moles or dark skin spots for melanoma. In particular, the PLA detected expression of the LINC00518 ("LINC") and preferentially expressed antigen in melanoma ("PRAME") genes using an amplification process called reverse transcription-polymerase chain reaction ("RT-PCR"). The Company introduced its second-generation PLA test, PLAplus^TM, in 2021, which could also identify the presence of TERT using a DNA sequencing technique and adding the TERT promoter mutation analyses to the PLA gene expression test. We have since rebranded our PLA and PLAplus tests as the DMT. The DMT tests for LINC and PRAME, and may be ordered with or without the add-on test for TERT. Positive results for LINC, PRAME, or TERT correlate with the presence of melanoma. If the biomarkers are not detected, this result indicates a greater than 99% probability that the mole being tested is not melanoma.
About DermTech
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart Stickers^TM. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "outlook," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products, DermTech’s positioning and potential revenue growth, financial outlook and future financial performance, ability to maintain or improve its operating efficiency and reduce operating expenses, implications and interpretations of any study results, expectations regarding agreements with or reimbursement or cash collection patterns from Medicare or commercial payers and related billing practices or number of covered lives, and DermTech’s ability to expand its product offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and commercial payers; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees and maintain or improve its operating efficiency and reduce operating expenses; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the "Risk Factors" section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the "SEC"), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005311/en/
Contacts
Steve Kunszabo
DermTech
(858) 291-1647
[email protected]
Related Quotes
Microsoft is reportedly considering a $10 billion investment in OpenAI, the creator behind the viral ChatGPT chatbot, Bloomberg reported on Tuesday.
For most of the last year, clinical-stage Athersys has been cutting costs to preserve its capital while looking for new partners to help launch its adult stem cell therapy.
Medical Properties Trust has been under a bear attack by short sellers
EVgo owns and operates a public direct current fast charging network in the U.S. EVgo’s network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. Its network is capable of charging all EV models and charging standards currently available in the U.S. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers (OEMs), hotels, shopping centers, gas stations, parking lot operators, local governments and independent property owners in order to locate and deploy its EV charging infrastructure.
Yahoo Finance's Seana Smith, Josh Schafer, and Dave Briggs discuss why Sotera Health stock is surging 99% on Tuesday.
Instil Bio Inc (NASDAQ: TIL) has resumed its Phase 1 clinical trial of ITIL-306 for non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC). With the resumption of the ITIL-306 Phase 1 study, the company plans to release initial safety, translational, and efficacy data from dose escalation cohorts at a medical conference in 2023. The trial was resumed after implementing additional quality safeguards designed to further protect the manufacturing process from potential c
Liver and gallbladder cancer in dogs is a condition where a dog develops cancer of the liver and gallbladder at the same time. The cause is often unknown.
Jill Biden was scheduled to undergo surgery on Wednesday to remove a potentially cancerous lesion above her right eye. The first lady's office announced a week ago that doctors had discovered the lesion during a recent routine skin cancer screening. President Joe Biden accompanied his wife to Walter Reed National Military Medical Center in Bethesda, Maryland, where she was to undergo a “common outpatient procedure known as Mohs surgery to remove and definitively examine the tissue,” said Dr. Kevin O'Connor, the president's physician, in a Jan. 4 memo that the first lady's office released last week.
Coinbase Global said that it would eliminate around 20% of its staff and enact broad cost cuts, the latest sign of pain in the cryptocurrency industry. Chief Executive Brian Armstrong said in a blog post Tuesday that crypto exchange Coinbase will reduce operating expenses by 25% from the previous quarter, including laying off about 950 people. Crypto lender Genesis Global Trading Inc. eliminated about a third of its staff last week, and crypto exchange Huobi recently said it plans to lay off about a fifth of its staff.
British luxury carmaker Bentley on Tuesday reported record vehicle sales for 2022, with strong demand offsetting a 9% drop in China caused by coronavirus-related lockdowns. The Volkswagen unit said it had sold 15,174 vehicles during 2022, up 4% from in 2021, which was itself a banner year for Bentley. "In what was another year of unpredictability, the business overcame significant headwinds and demonstrated great resilience to deliver the third consecutive record sales year," Bentley CEO Adrian Hallmark said in a statement.
You might think fourth quarter earnings reports are ugly if you're just looking at the S&P 500. More than a few stocks buck the trend.
SINGAPORE (Reuters) -Standard Chartered is considering a sale, among several options, of its aviation unit, which according to an industry publication owns a fleet worth around $3.7 billion. "We believe that a new owner can drive the next phase of growth whilst we continue to focus on our commitment to improve shareholder returns and delivering on our 2024 targets," Simon Cooper, CEO of StanChart's corporate, commercial & institutional banking business, said in a statement. StanChart's aviation financing business was ranked as the 21st biggest lessor based on the $3.7 billion market value of its fleet in publisher Airfinance Journal's 2022 rankings.
The Haynesville basin in Louisiana and Texas is humming with drillers. Among them is Chesapeake, a fracking pioneer that was in bankruptcy just two years ago.
What makes a good manager? New research from BCG decodes the DNA of great people managers.
The charts here are neutral now, but any large dips will likely be fantastic long-run setups for the bulls.
With Wall Street increasing its expectations for a recession in 2023, investors should look for sectors that are expected to either thrive or at least hold their own during the worst of times. One such sector is healthcare. People get sick or injured whether the economy is in a boom or bust cycle. It’s not surprising that one of the best-performing real estate investment trust (REIT) sectors in recent weeks has been healthcare, with several stocks rising in price. Take a look at the three best-p
For its part, Berkshire Hathaway has seen its shares outperform the S&P 500. Now, despite the recent underperformance of Apple — Berkshire's largest position — shares of Berkshire Hathaway are trying to break out. Before we dive into the setup, notice how Berkshire stock was hitting all-time highs in late March.
The GE HealthCare Technologies spinoff will have numbers all over the place for the next month or two.
LVMH Chairman and CEO Bernard Arnault has reshuffled top management at his luxury goods empire, tightening his family's grip with the appointment of his daughter Delphine to lead Christian Dior, and naming a new boss for Louis Vuitton. Pietro Beccari, who has been the head of Dior since 2018, is moving to replace long-time Louis Vuitton CEO Michael Burke, 65. Shares in LVMH, Europe's most valuable company at about 380 billion euros ($408 billion), rose as much as 2% to hit new highs.
Linde shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

source